Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents.ARC004, the open-label follow-on study to PALISADE, used 5 dosing cohorts to explore P...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | 英语 |
出版: |
2020
|
在線閱讀: | https://doi.org/10.1016/j.jaip.2020.12.029 http://www.jaci-inpractice.org/article/S2213219820313611/pdf |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|